INTRODUCTION
Overactive bladder (OAB) syndrome is a condition that accom panies urgency, with or without urge incontinence, frequently with increased daytime frequency and nocturia (1) . Urgency, the main symptom of OAB, seems to affect nocturia and incon tinence (2) . The International Continence Society defines noc turia as waking to void one or more times during the night (3) . Nocturia is the most common storage symptom in the general population (4) . Nocturia is due to nocturnal polyuria, a decre ased nocturnal bladder capacity, or a mixture of these 2 terms (5). Various duplicating factors for nocturia have been reported, including pathological conditions such as diabetes, lower uri nary tract disorder, cardiovascular disease, primary sleep disor ders, and sleep apnea (6) . Nocturia can significantly influence quality of life, efficiency, vigor, and awareness of health, primar ily due to sleep disruption (7, 8) . Thus, the feasibility for the bet terment of nocturia may increase sleep quality. Moreover, ur gency, which is a key symptom of OAB, is also a significant fac tor for sleep disruption (9) . Antimuscarinic drugs, the most appropriate treatment for OAB, improve urination urgency and frequency and effectively reduce involuntary contractions and increase bladder capacity in patients with storage symptoms (1012). Solifenacin succi nate (Vesicare; Astellas Pharma Co. Ltd., Tokyo, Japan) is a once daily oral agent that is particularly effective in the bladder (13) . In phase 2 and 3 trials, solifenacin has shown significantly de creased frequency and significantly increased voiding volume in symptomatic OAB patients (14, 15) .
Solifenacin is an antimuscarinic drug that is indicated for the treatment of OAB. OAB symptoms respond to extendedrelease solifenacin. Peak plasma concentrations of solifenacin are reach ed 3-8 hours after absorption from the gut (13) . Thus, nighttime dosing with solifenacin would more effectively improve night time symptoms such as nocturia. Moreover, the nighttime dos ing of antimuscarinic drugs may improve tolerance compared with daytime dosing (16, 17) . Although several recent studies reported the efficacy of antimuscarinic agents on nocturia and sleep disturbances, these analyzed efficacy regardless of ad ministration time (1820). Therefore, we compared changes in https://doi.org/10.3346/jkms.2017.32.9.1491 nocturia and sleeprelated parameters between daytime and nighttime solifenacin dosing in patents with OABassociated nocturia.
MATERIALS AND METHODS

Study design and participants
We performed comparative analyses of data from a 12week prospective, openlabel multicenter, randomized study (Ulsan University Hospital, Samsung Changwon Hospital, Kosin Uni versity Gospel Hospital, DongA University Hospital, and Pusan National University Hospital). All patients were assessed by a diseasespecific selfreported questionnaire including the In ternational Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), and Athens Insomnia Scale (AIS). OA BSS is obtained as the total of 4 symptom scores that address frequency in daytime, frequency in night time, urgency, and urgency incontinence. The maximum scores for each compo nent were defined as 2, 3, and 5, respectively (21) . The AIS is a selfadministered questionnaire consisting of 8 items. Each item on the AIS can be rated from 0 (no problem at all) to 3 (very se rious problem) (22) . The study criteria were follows: nocturia ≥ 2 (times per night), OABSS scale 2 ≥ 2, OABSS scale 3 ≥ 2, and AIS ≥ 6. Patients with urethral stricture, severe bladder outlet obstruction, bladder stones, active urinary tract infection, or chro nic bacterial prostatitis were excluded from the study.
All 127 patients who presented to 5 centers in Korea for the treatment of OAB with nocturia between January 2011 and De cember 2013 were enrolled in this study. All patients took solif enacin 5 mg once per day for > 12 weeks. Participants were then randomly assigned in a 1:1 ratio to group 1, daytime dosing; and group 2, nighttime dosing. Daytime dosing occurred after break fast, while nighttime dosing occurred after dinner. We evaluat ed the changes of each parameter before and 12 weeks after daytime or nighttime solifenacin administration. This analysis of nocturia data included patients who completed a bladder di ary for 3 consecutive days, whose voiding frequency and voided volume were recorded, and who voided at least once during the night with a mean of 2 nighttime records at baseline. The analysis included patients who continued treatment during the study period and those who completed efficacy and symptom assessments at baseline as well as at 12 weeks.
Adverse events (AEs) were assessed for patients who took at least 1 dose of solifenacin. AEs reported in response to general and nonspecific questioning by the researcher or selfreported by the patient were described with severity at each visit. Safety evaluation at weeks 4, 8, and 12 included vital sign, physical ex amination finding, and AE recordings. The postvoid residual volume was measured by bladder scanning at the start and end of the 12week treatment period.
Statistical analysis
The 2 groups were compared in terms of clinical characteristics using Pearson's χ 2 test for categorical variables and Student's t test for continuous variables. The quantitative data are expressed as mean and standard deviation. The number of voiding episo des per night, nighttime voided volume, AIS, IPSS, and OABSS were compared between baseline and 12 weeks after adminis tration in each patient group. Efficacy measured between the groups included the mean change from baseline to 12 weeks in the number of voiding episodes per night, nighttime voided volume, AIS, IPSS, and OABSS. Pearson correlation testing was used to examine the correlation among AIS, OABSS, and noc turia. All statistical tests were 2sided, and values of P < 0.050 were considered significant. The data were analyzed using IBM SPSS Statistics version 21 (IBM, Somers, NY, USA).
Ethics statement
The study protocol was approved by the Institutional Review Board at all sites (IRB No. 2011007). Informed consent was ob tained by all subjects when they were enrolled.
RESULTS
The mean age of the entire cohort was 59.2 years; and all pati ents presented for treatment of OAB with nocturia. Of these pa tients, 62 (48.8%) with daytime dosing were assigned to group 1 and 65 (51.2%) with nighttime dosing were assigned to group 2. The descriptive characteristics by group are presented in Table  1 . Baseline data, which included sex, age, BMI, AIS, total IPSS, and OABSS did not differ between the 2 groups. Mean nocturia before treatment of the whole cohort was 2.4 ± 1.0 episodes per night, but no difference was noted between groups 1 and 2 (2.4 ± 0.8 vs. 2.3 ± 1.1; P = 0.895). Table 2 shows changes from baseline after 12 weeks of solife nacin in each group. Total AIS significantly improved from 11.6 at baseline to 7.2 at 12 weeks in group 1 and from 10.4 to 6.4 in group 2 (P < 0.001). The OABSS significantly improved from 8.8 at baseline to 4.6 at 12 weeks in group 1 and from 8.1 to 4.6 in group 2 (P < 0.001). Total IPSS and nocturia also significantly improved after solifenacin administration regardless of admin istration timing (P < 0.001). Although there were no statistically significant differences, mean nocturia volume also improved from 406 mL at baseline to 213 mL after 12 weeks in group 1 (P = 0.325) and from 442 mL to 268 mL in group 2 (P = 0.204). Postvoid residual urine volume increased from 20.3 mL at base line to 32.4 mL at 12 weeks in group 1 and from 15.9 mL to 32.3 mL in group 2, but there were no significant differences.
Between groups, there was no statistically significant differ ence in change of total AIS, IPSS, OABSS, and nocturia before treatment and after 12 weeks of solifenacin (Table 3) . Although almost every category except residual urine improved at 12 weeks after solifenacin administration, and there were no significant differences by administration timing. We also assessed the cor relation between improved AIS and OABSS and decreased noc turia. We found a correlation between AIS improvement and decreased nocturia from the patient's record (r = 0.303; P = 0.023) and between OABSS improvement and decreased nocturia (r = 0.146; P = 0.383).
There were no cases of discontinuation because of AEs. The overall AE incidence was 13.3% (17/127). The percentages of AEs were 14.5% (9/62) and 12.3% (8/67) in groups 1 and 2, re spectively (P = 0.797). Among the treatment groups, the inci dence of the most common AE, dry mouth was similar for the 2 groups (11.2% in group 1 and 7.7% in group 2, P = 0.458). Con stipation, which was mainly mild in all cohorts, occurred in 3.2% of patients in group 1 and 4.6% of patients in group 2. The inci dence of constipation was not statistically different between the groups (P = 0.696).
DISCUSSION
This study is the first to evaluate the influence of daytime or nighttime solifenacin dosing in patients with OAB and noctu ria. A strict definition of nocturia was used as the inclusion cri terion in this study; only patients with ≥ 2 episodes of nocturia were enrolled. Moreover, urgency is the main condition of OAB; therefore, patients who also had urgency (OABSS scale 3 ≥ 2) were enrolled. As a result, our data advocated that solifenacin had the possibility to improve OAB symptoms and sleep quality of patients with sleep disruption and nocturia, which coincides with previous solifenacin clinical studies (18, 19) . Both nocturia and urgency are significant factors for sleep disruption. Thus, using antimuscarinic agents to improve urgency may increase bladder stability and improve sleep quality (9) .
The AIS is a selfrating inventory consisting of 8 objectives (22, 23) . The first 5 assess difficulty falling asleep, awakening dur ing the sleep, early morning awakening, total sleep duration, and overall sleep quality, which are representative of nocturnal AIS. The last 3 items are related to the daytime consequences of insomnia. This study also showed that AIS improvement after (24) . Although no statistically significant differences were detected, the mean nocturia volume was also reduced in our study. This means that anticholinergic drug use decreases the nocturnal urine volume. Solifenacin is an excellent drug with few AEs associated with the treatment of OAB with daytime dosing (18, 19) . The results from our study proved that the 24hour clinical effect of solife nacin persisted with nighttime dosing. A significant reduction in OAB symptoms, nocturia, and sleep disturbances was achi eved regardless of administration time. The nighttime dosing of antimuscarinic drugs may improve tolerance compared with daytime dosing (16, 17) . In our study, the overall incidence of AEs was 13.3%, similar between the 2 groups. Although the study populations were different, the lower AE rates in other studies suggest that, in addition to continuing 24hour efficacy, night time dosing may further reduce the AEs related to antimusca rinic therapy (16, 25) . The maximum serum solifenacin concen tration is reached 3-8 hours after absorption from the gut (13) , and the maximum concentration is likely associated with anti cholinergic AEs. Therefore, lower AE rates related with night time dosing may be related to the maximum serum concentra tions being reached while the patients were sleeping.
Our study has some limitations. First, it was not a placebo controlled study, so we could not investigate the placebo effect. We also did not conduct urodynamics studies in our patients; rather, we diagnosed OAB using a questionnaire. Furthermore, we could not identify the direct relationship between urgency and sleep quality. Finally, although daytime or nighttime dos ing of the anticholinergic drug solifenacin improved OAB symp toms and sleep disturbance, we could not know whether the small reduction in nocturia and the increase in sleep may actu ally improve patient satisfaction or quality of life. A further study that includes more patients is needed to solve these problems.
In conclusion, our study confirmed that the improved urgen cy and nocturia by solifenacin administration may also improve sleep quality. However, there were no significant differences by administration timing. Although there are various cau ses of noc turia, this antimuscarinic drug may not only improve storage symptoms by decreasing urgency and nocturia but also improve sleep disruption for OAB patients with sleep disruptions.
